Oxford Biomedica’s long-running alliance with Sanofi over a pair of gene therapies for ophthalmic diseases has come to an end, after an internal review by the French drugmaker.
Sanofi has just spent $16 billion on acquiring Bioverativ and Ablynx – and yesterday’s Q4 results revealed why the firm is in a hurry to diversify its revenues.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh